Generated July 2026 from current fund data.
Overview
DRAM and SOXX both target semiconductor exposure but through fundamentally different lenses. SOXX is a broad-market index tracker of US-listed semiconductor companies with two decades of history, while DRAM is a thematic growth fund launched recently that focuses specifically on memory-chip technology and artificial intelligence applications. The choice between them hinges on whether you want diversified semiconductor exposure or concentrated play on memory's AI tailwinds.
How they differ
SOXX tracks the entire US semiconductor industry via the ICE Semiconductor Index, whereas DRAM narrows its lens to memory chips and AI-related memory applications—a structural difference that explains their vastly different risk profiles. SOXX pays a 0.21% distribution yield quarterly and has an expense ratio of 0.35%, while DRAM does not distribute and carries a 0.65% expense ratio, reflecting its active thematic strategy versus passive indexing. SOXX's beta of 2.24 signals it amplifies broad market moves roughly twice over; DRAM reports a beta of 0.0, which is unusual for an equity fund and warrants scrutiny about what that calculation reflects. SOXX commands $45.5B in assets against DRAM's $23.4B, and SOXX's 23-year track record contrasts sharply with DRAM's inception date listed as April 2026—a data anomaly suggesting DRAM may be newly launched or recently restructured.
Who each is best for
SOXX: Fits investors seeking diversified semiconductor exposure through a passive, low-cost index approach with a modest quarterly dividend; designed for those comfortable with the cyclicality and geopolitical risk of the broader chip industry.
DRAM: Fits investors who believe memory and AI-powered memory technology will outpace the broader semiconductor sector and are willing to accept higher fees and concentration risk for thematic upside; suits longer time horizons given the absence of distributions.
Key risks to know
- DRAM concentration and sector rotation: Memory chips are a subset of semiconductors; if the sector rotates away from memory-intensive AI workloads or toward logic and design, DRAM's narrower mandate could underperform SOXX significantly. Holdings likely overlap with SOXX but with far higher weighting in memory leaders.
- SOXX cyclicality and geopolitical exposure: The semiconductor industry is capital-intensive, cyclical, and heavily exposed to US-China trade and supply-chain policy. A downturn in chip demand or tighter export controls could pressure valuations across the entire index.
- DRAM beta and valuation uncertainty: A reported beta of 0.0 for an equity thematic fund is inconsistent with normal stock behavior and suggests either a data reporting issue or unusual hedging; investors should confirm how the fund is actually moving relative to tech and broader markets before committing.
- SOXX beta amplification: A beta of 2.24 means SOXX roughly doubles broad market swings; in a sharp tech or market correction, losses could be severe relative to the overall market.
- DRAM's nascent track record: The fund's recent inception date limits historical performance visibility, making it harder to assess how its thematic strategy has weathered prior semiconductor cycles or AI hype reversals.
Bottom line
SOXX offers diversified, low-cost, dividend-paying exposure to the entire US semiconductor supply chain with a long operating history; DRAM bets narrowly on memory's AI-driven upside with no distributions and higher fees. If you want broad semiconductor participation with downside visibility, SOXX's index approach and lower expense ratio stand out; if you're convinced memory and AI form the industry's primary growth driver and can tolerate concentration risk, DRAM's thematic focus may appeal. Past performance does not predict future results, and the semiconductor sector's capital intensity and policy sensitivity mean both funds carry material drawdown risk in adverse cycles.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.